Advent France Biotechnology (AFB) and Invivo Ventures have invested in a €4.25m round for Spanish life sciences company Arthex Biotech, which develops RNA therapies for the treatment of myotonic dystrophy.
Advent France Biotechnology (AFB) and Invivo Ventures have invested in a €4.25m round for Spanish life sciences company Arthex Biotech, which develops RNA therapies for the treatment of myotonic dystrophy.